Value | Commercial | Access

This month we are reading about:

  • non-DiGA pathways for digital app reimbursement in Germany.
  • need for change in reimbursement and patient value definitions in an ever more personalised care environment
  • gene therapies and microbiome medicines entering the market right now
  • evidence requirements for faster HTA

Have a good read!

Other recent posts: